Vonapanitase Misses Key Target in Chronic Kidney Disease Blood-Flow Study
News
The experimental treatment vonapanitase failed to improve a key barometer of unassisted blood flow in a Phase 3 study of patients with chronic kidney disease (CKD), according to its maker, Proteon Therapeutics. ... Read more